Promising therapies for cholesterol reduction.
D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000145:classification / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000517:prevention & control; D001384:Azetidines / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL / Q000037:antagonists & inhibitors / Q000097:blood; D000069472:Colesevelam Hydrochloride; D000069438:Ezetimibe; D006023:Glycoproteins; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors; D013451:Sulfonic Acids / Q000627:therapeutic use; D014157:Transcription Factors / Q000627:therapeutic use; D014481:United States
D000924:Anticholesteremic Agents; D001384:Azetidines; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL; D006023:Glycoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D013451:Sulfonic Acids; D014157:Transcription Factors; C106092:microsomal triglyceride transfer protein; D000499:Allylamine; D002785:Sterol O-Acyltransferase; D000069438:Ezetimibe; D000069472:Colesevelam Hydrochloride